Reata Pharmaceuticals Inc (Reata) is a clinical-stage biopharmaceutical company. It develops innovative medicines for the treatment of serious and life-threatening diseases. The company's clinical candidates include bardoxolone methyl and omaveloxolone, which target Nrf2, a transcription factor, for restoring mitochondrial function, reducing oxidative stress, and resolving inflammation. Its products also include HSP90 modulators, RTA 901, RORγt inhibitors, and RTA 1701. Reata is evaluating bardoxolone methyl in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH), alport syndrome and other kidney diseases; and omaveloxolone in Friedreich’s ataxia. The company works in partnership with academics, biotechnology, and pharmaceutical companies to develop technologies. It has operations in the US, the UK, Ireland, Australia and Switzerland. Reata is headquartered in Plano, Texas, the US.
Headquarters
United States of America
Address
5320 Legacy Dr, Plano, Texas, 75024-3127
Website
www.reatapharma.com
Telephone
1 972 8652219
No of Employees
346
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
RETA (NASD)
Revenue (2021)
$11.5M
27.4%
(2021 vs 2020)
EPS
XXX
Net Income (2021)
XXX
-20%
(2021 vs 2020)
Market Cap*
$1.2B
Net Profit Margin (2021)
XXX
5.8%
(2021 vs 2020)
* As of and is in US$
Explore premium data & analytics
Products and Services
| Products |
|---|
| Bardoxolone Methyl and Omaveloxolone |
| RTA 901 |
| RTA 1701 |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2022 | Regulatory Approval | In February, the company announced the completion of the rolling submission for omaveloxolone for the treatment of patients with Friedreich’s ataxiato with the U.S. Food and Drug Administration. |
| 2022 | Regulatory Approval | In February, the company announced the U.S. Food and Drug Administration issued a Complete Response Letter for the New Drug Applicatio for bardoxolone methyl (“bardoxolone”) to treat patients with chronic kidney disease. |
| 2022 | Regulatory Approval | In January, the company initiated a rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for omaveloxolone for the treatment of patients with Friedreich’s ataxia. |
Competitor Comparison
| Key Parameters | Reata Pharmaceuticals Inc | Bayer AG | Sanofi | AstraZeneca Plc | Eli Lilly and Co |
|---|---|---|---|---|---|
| Headquarters | United States of America | Germany | France | United Kingdom | United States of America |
| City | Plano | Leverkusen | Paris | Cambridge | Indianapolis |
| State/Province | Texas | Nordrhein-Westfalen | - | Cambridgeshire | Indiana |
| No. of Employees | 346 | 100,753 | 95,442 | 83,100 | 35,000 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Operating Margin
EPS (Earnings per Share)
Debt to Equity Ratio
Return on Assets
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Warren Huff | Chairman; Chief Executive Officer | Executive Board | 2002 | 68 |
| Manmeet S. Soni | Chief Operating Officer; President; Chief Financial Officer | Senior Management | 2022 | 44 |
| Bhaskar Anand | Chief Accounting Officer; Vice President | Senior Management | - | - |
| Michael D. Wortley | Executive Vice President; Chief Legal Officer | Senior Management | 2015 | 74 |
| Samina Khan | Senior Vice President; Chief Medical Officer | Senior Management | 2020 | 57 |
| Non Dignissim Eros | Proin vel | Convallis | 2022 | XX |
| Non Dignissim Eros | Proin vel | Convallis | 2022 | XX |
| Non Dignissim Eros | Proin vel | Convallis | 2022 | XX |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer